

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30 th June 2019

PART I		[Rs. In Lakhs] except EPS					
Sl.No	Particulars	3 months ended (30-06-2019) standalone	Preceding 3 months ended (31-03-2019) standalone	Corresponding 3 months ended (30.06.2018) standalone	Consolidated Upto 3 months ended (30.06.2019)	For the Previous Year ended (31.03.2019) standalone	Consolidated For the Previous Year ended (31.03.2019)
		Unaudited	Audited	Unaudited	Unaudited	Audited	Audited
I	Revenue From operations	684.93	949.48	1,195.13	684.93	4,335.89	4,335.89
II	Other Income	30.17	27.62	9.19	30.17	65.36	65.36
III	Total Income (I+II)	715.09	977.10	1,204.31	715.09	4,401.25	4,401.25
IV	EXPENSES						
a)	Cost of materials consumed	694.61	742.04	1,093.80	694.61	3,329.44	3,329.44
b)	Purchases of Stock-in-Trade	-	15.68	15.00	-	46.36	46.36
c)	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	(60.34)	139.24	(5.08)	(60.34)	81.14	81.14
d)	Employee benefits expense	231.49	267.08	194.31	231.49	901.29	901.29
e)	Finance costs	12.68	21.16	83.21	12.68	342.17	212.66
f)	Depreciation and amortization expenses	101.78	76.72	100.00	101.78	212.64	347.62
g)	Other expenses	105.84	1,065.43	78.56	105.84	1,311.18	1,312.03
	Total expenses (IV)	1,086.06	2,327.35	1,559.81	1,086.06	6,224.22	6,230.53
V	Profit/(loss) before exceptional items and tax (I-IV)	(370.96)	(1,350.25)	(355.50)	(370.96)	(1,822.97)	(1,829.28)
VI	Exceptional Items						100.99
VII	Profit/ (loss) before exceptions items and tax(V-VI)	(370.96)	(1,350.25)	(355.50)	(370.96)	(1,822.97)	(1,728.29)
VIII	Tax expense:						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	(158.21)	149.36	(4.19)	(158.21)	150.07	106.74
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	(212.75)	(1,499.61)	(351.31)	(212.75)	(1,973.04)	(1,835.03)
X	Profit/(loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(212.75)	(1,499.61)	(351.31)	(212.75)	(1,973.04)	(1,835.03)
	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
XIV	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(52.01)
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	(212.75)	(1,499.61)	(351.31)	(212.75)	(1,973.04)	(1,887.05)
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	(0.90)	(6.34)	(1.49)	(0.90)	(8.34)	(11.44)
	(2) Diluted	(0.90)	(6.34)	(1.49)	(0.90)	(8.34)	(11.44)
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XVIII	Earning per equity share (for discontinued & continuing operation)						
	(1) Basic	(0.90)	(6.34)	(1.49)	(0.90)	(8.34)	(11.44)
	(2) Diluted	(0.90)	(6.34)	(1.49)	(0.90)	(8.34)	(11.44)

- The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 10.08.2019
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The above figures have been regrouped and Re-arranged Wherever considered necessary
- Being the First Quarter of the year, Figures of the Quarter ended 30th June 2019 and Year to date for this Quarter are same hence not mentioned separately.

For BAFNA PHARMACEUTICALS

Place: Chennai
Date: 10.08.2019

(Signature)
(BAFNA MAHA VEER CHAND)
MANAGING DIRECTOR
DIN:01458211

